New insulin cocktails aim to speed up meal coverage for type 1 diabetes
NCT ID NCT07090824
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests whether two modified insulins (diluted U-200 Humalog and diluted U-500 Humulin) work faster than a current rapid insulin (Lyumjev) in 20 adults with type 1 diabetes who use insulin pumps. Participants receive each insulin after a meal, and researchers measure how quickly and how long the insulin stays in the blood. The goal is to find insulins that act faster to better cover meals without needing to dose beforehand.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
modified insulin formulations (diluted U-200 Humalog and diluted U-500 Humulin)
What this could lead to
If successful, this could point toward faster-acting insulins that improve blood sugar control after meals for people with type 1 diabetes using insulin pumps.
What could go wrong
This is a very small, early-phase study with only 20 people. It measures insulin levels in the blood, not actual blood sugar outcomes, so it may not lead to a practical treatment change.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••